

Global Health Lecture Series

Sm-p80-based Schistosomiasis Vaccine: Update on Human Clinical Trials

featuring

Afzal A. Siddiqui, PhD

Grover E. Murray Professor

TTUHSC Lubbock

Wednesday, March 27

Noon

ACB 110

Zoom: <https://ttuhsc.zoom.us/j/9798966879>

Afzal A. Siddiqui, Ph.D. is a Grover E. Murray Professor. He has developed a vaccine for schistosomiasis. Schistosomiasis is endemic in 78 developing countries; two hundred and fifty million people are infected by it and an additional 800 million people are at risk of acquiring it. The vaccine has the potential of positively impacting one billion people. The journal Science listed a schistosomiasis vaccine among the top-10 priority vaccines needing to be developed. The vaccine, SchistoShield® (Sm-p80 plus GLA-SE) developed by Dr. Siddiqui is deemed one of the most promising among candidate vaccines for this disease in light of numerous nonhuman primate studies. SchistoShield® is now entering its first in-human trials. A toxicology study is being executed and a phase 1 human clinical trial, funded by the National Institutes of Health has commenced in the United States. The next steps include phase 1b trials that are planned for later in 2019 to be conducted in two endemic countries in Africa.

Free lunch will be provided to the first 50 attendees (*Lubbock campus only*).

This event is free & open to the public. No RSVP is necessary.

For more information about the Global Health Lecture Series, contact the Office of Global Health at 806-743-2901 or globalhealth@ttuhsc.edu.

Persons needing assistance should contact the Office of Global Health for arrangements.